Search clinical trials for: γ-linoleic acid and placebo(Thioctic Acid)

Total 23871 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Donor | Hematopoietic Cell Transplant Recipient | HLA-A*0201 Positive Cells Present

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Cholangiocarcinoma | Metastatic... and other conditions

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
City of Hope Medical Center

Active, not recruiting

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
National Cancer Institute (NCI)

Recruiting

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Puerto Rico, Israel
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Ph-Like Acute Lymphoblastic Leukemia

United States
Zagazig University

Completed

Evidence Based Management of Acute Biliary Pancreatitis

Acute Pancreatitis

Egypt
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma

United States, Australia, Canada, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
Vanderbilt University

Completed

Treatment of Orthostatic Hypotension in Autonomic Failure

Orthostatic Hypotension | Autonomic Failure

United States
National Cancer Institute (NCI)

Terminated

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Freeman-Sheldon Research Group, Inc.

Terminated

Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions (FSS-QLS)

Depressive Disorder | Craniofacial Abnormalities | Posttraumatic Stress Disorder | Arthrogryposis

United States, Guatemala
Mayo Clinic
National Cancer Institute (NCI)

Completed

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

Glioblastoma | Malignant Glioma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | HLA-A*0201 Positive Cells Present | COL6A3 Positive | PRAME Positive

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Suspended

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Non-Malignant Neoplasm

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
University of Washington
AbbVie

Suspended

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Mixed Phenotype Acute Leukemia | Myeloid Neoplasm | Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia | Relapsed Acute Myeloid Leukemia | Mixed Phenotype Acute Leukemia | Relapsed Acute Biphenotypic Leukemia | Relapsed... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
University of New Mexico
Patient-Centered Outcomes Research Institute; Montana State University; National... and other collaborators

Terminated

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Bipolar Disorder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells Present

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Amyloidosis | Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient

United States
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
Fred Hutchinson Cancer Center
National Cord Blood Network

Recruiting

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Chronic...

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor

United States, Canada, Australia, New Zealand, Puerto Rico, Israel, Switzerland
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Terminated

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

Recurrent Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 | Stage II Adult Soft Tissue Sarcoma AJCC v7 | Stage III Adult Soft Tissue Sarcoma AJCC v7

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor

United States, Canada, Australia, New Zealand, Puerto Rico, Israel, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States

Search clinical trials for: γ-linoleic acid and placebo(Thioctic Acid)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations